Literature DB >> 16238978

[Ophthalmoplegia in a patient with prostate cancer and bone metastases].

Sonia Maciá Escalante1, Carmen Guillén Ponce, Maria José Molina Garrido, Maria José Martínez Ortiz, Inmaculada Ballester Navarro, Alfredo Carrato Mena.   

Abstract

Prognosis in prostate cancer is determined, in greater part, by the presence of metastases. Bone metastases can occur in any part of the skeleton even, for example, at the base of the skull. We present a case of a 78 year old male who, in December 2001, presented with paralysis of the third cranial nerve. The NMR and CAT scans were normal and circulating levels of PSA were elevated. He was referred to the Urology Service where the treatment guidelines included complete androgen block. Subsequently, he developed retro-orbital pain, divergent strabismus and palpebral ptosis. CAT and NMR indicated a soft tissue mass at the sphenoid level. Treatment was Gamma Knife Radio-surgery. Since August 2004, in conjunction with the latest rise in PSA, the patients general status deteriorated considerably and he was referred to the Oncology Service. There was an increase in the paralysis of the third, fourth and sixth cranial nerve (complete left ophthalmoplegia) and left-central facial paralysis. Metastases from prostate cancer can be disseminated via the lymphatic or the blood system. Currently, there are more metastases from large-size tumours. Metastases are critical in prostate cancer because of their adverse effect on the patients survival. Measurements of circulating levels of prostate specific antigen and prostate acid phosphatase are very useful in the clinical diagnosis of the primary tumour, or its metastases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16238978     DOI: 10.1007/bf02716589

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  8 in total

1.  Orbital metastases: diagnosis and course.

Authors:  D H Char; T Miller; S Kroll
Journal:  Br J Ophthalmol       Date:  1997-05       Impact factor: 4.638

2.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Authors:  G J Bubley; M Carducci; W Dahut; N Dawson; D Daliani; M Eisenberger; W D Figg; B Freidlin; S Halabi; G Hudes; M Hussain; R Kaplan; C Myers; W Oh; D P Petrylak; E Reed; B Roth; O Sartor; H Scher; J Simons; V Sinibaldi; E J Small; M R Smith; D L Trump; G Wilding
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

3.  Features of unusual metastases from prostate cancer.

Authors:  M A Long; J E Husband
Journal:  Br J Radiol       Date:  1999-10       Impact factor: 3.039

4.  Prostate tumor progression and prognosis. interplay of tumor and host factors.

Authors: 
Journal:  Urol Oncol       Date:  2000-11-01       Impact factor: 3.498

Review 5.  Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.

Authors:  E J Small; N J Vogelzang
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

Review 6.  Pathological and molecular aspects of prostate cancer.

Authors:  Angelo M DeMarzo; William G Nelson; William B Isaacs; Jonathan I Epstein
Journal:  Lancet       Date:  2003-03-15       Impact factor: 79.321

Review 7.  Tumors metastatic to the pituitary gland: case report and literature review.

Authors:  John Komninos; Varvara Vlassopoulou; Despina Protopapa; Stefanos Korfias; George Kontogeorgos; Damianos E Sakas; Nicolas C Thalassinos
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

8.  Symptomatic pituitary metastases.

Authors:  A Morita; F B Meyer; E R Laws
Journal:  J Neurosurg       Date:  1998-07       Impact factor: 5.115

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.